Emily Barney

Emily Barney

Auto-generated profile, based on publicly available information

Emily Barney

Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina; the Anesthesia Medical Group, Inc., Nashville, Tennessee; and the Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, Los Angeles, California

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
EBEmily Barney
Emily Barney
MDMichael R. Dores
Michael R. Dores
DMDanielle McAvoy
Danielle McAvoy
PDPerry Davis
Perry Davis
RRRona-Cristina Racareanu
Rona-Cristina Racareanu
Robert M. DoresRobert M. Dores
Robert M. Dores

9 February 2020 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
EBEmily Z. Bs Barney
Emily Z. Bs Barney
CPChristina D. Pedro
Christina D. Pedro
BGBrock H. Gamez
Brock H. Gamez
MFMatthew E. Fuller
Matthew E. Fuller
JDJennifer E. Md Dominguez
Jennifer E. Md Dominguez
AHAshraf S. Mbbch Habib
Ashraf S. Mbbch Habib
OBJECTIVE: To evaluate the efficacy of wound infusion with ropivacaine plus ketorolac compared with placebo for post–cesarean delivery analgesia in women who received a multimodal analgesic regimen including intrathecal morphine. METHODS: In a randomized double-blind study, women undergoing scheduled cesarean delivery under spinal or combined spinal epidural anesthesia were randomized to wound infusion with ropivacaine 0.2% plus ketorolac, or saline placebo using an elastometric pump for 48 hours. The primary outcome was pain score with movement at 24 hours after surgery (0–10 scale, 0=no pain and 10=worst possible pain). Secondary outcomes included pain scores at rest at 24 hours, pain scores at rest and with movement at 2 and 48 hours, opioid consumption, and time to first rescue analgesic. A sample size of 35 per group (n=70) was planned. RESULTS: From November 8, 2016, to May 17, 2019, 247 women were screened, and 71 completed the study per protocol: 38 in the placebo group and 33 in the ropivacaine plus ketorolac group. Patient demographics and intraoperative characteristics were comparable between the groups. There was no significant difference between the groups in the primary outcome of pain score with movement at 24 hours (difference in median score 0, 95% CI −1 to 2, P=.94). There were also no significant differences between the placebo and ropivacaine plus ketorolac groups in pain scores at other time points, in total opioid consumption (difference in median consumption −12.5 mg, 95% CI −30 to 5, P=.11), or in time to rescue analgesics (median [interquartile range] 660 [9–1,496] vs 954 [244–1,710] minutes, hazard ratio 0.69, 95% CI 0.41 to 1.17, P=.16). CONCLUSION: There was no benefit of wound infusion with ropivacaine and ketorolac in women who received intrathecal morphine and a multimodal analgesic regimen. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02829944. FUNDING SOURCE: The study was supported in part by Avanos Medical Inc.

5 March 2019 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
EBEmily Barney
Emily Barney
NPNeil S. Prose
Neil S. Prose
MRMary Ramirez
Mary Ramirez